The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cellsF Grignani, Pier Giuseppe Pelicci, Pier Francesco Ferrucci et al.|Cell|1993Cited by 610
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Dirk Schadendorf, Georgina V. Long et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 146
Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.F Grignani, Pier Giuseppe Pelicci, Ugo Testa et al.|The EMBO Journal|1996Cited by 128
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trialPaul Nathan, Dirk Schadendorf, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 68
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Michele Maio, Pippa Corrie et al.|Journal of Clinical Oncology|2023Cited by 25